Selvita in Poland awarded the Great Place to Work® Certificate

Selvita Group continues its dynamic growth in the first quarter of 2022

Selvita sums up 2021 and announces Development Strategy for 2022-2025

AACR ANNUAL MEETING 2022

Immagene and Selvita Announce Integrated Drug Discovery Cooperation

Selvita heads towards new development phase

Selvita Group reports a dynamic increase in revenues for Q3 2021 YTD

Selvita Group reports over 109% increase in revenues for H1 2021

Selvita has received a grant to establish a technological platform, which will enable creation of new generation of drugs against diseases caused by coronaviruses

Webinar: Screening in drug discovery best practices: past, present, and future

Selvita will develop a platform to produce focused libraries of bioactive compounds with the use of machine learning and AI methods

Selvita appoints Dean Bornilla as Vice President of Sales, Head of North America

Selvita scales its operations with the construction of new research space

Ardigen webinar – “AI methods in small molecule design.”

Selvita Group reports over a two-fold increase in revenues for Q1 2021

Fidelta Webinar – “Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)”

Fidelta's Capabilities In Antiviral Drug Discovery

Selvita Webinar – “Analytical outlook for biosimilar development”

Breakthrough year in the development of Selvita – strategic acquisition & strong financial results

Selvita will participate in the upcoming BIO-Europe Spring 2021

Selvita named the Stock Exchange Company of the Year

Selvita enters the mWIG40 index

Selvita to present at the Precision In Drug Discovery & Preclinical Virtual Summit (West Coast)

Selvita develops the cell-based phenotypic assay platform for drug discovery

Webinar with live Q&A on modern small molecule drug discovery

Selvita completes acquisition of Fidelta from Galapagos

Selvita to acquire Fidelta from Galapagos
- Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe -

Selvita reports strong financial results for Q3 2020

Selvita will participate in the upcoming 5th Medicinal Chemistry & Protein Degradation Summit

Selvita will participate in the upcoming 26th annual BIO-Europe

Selvita Research Centre grant application recommended for financing

Selvita to present at the 20th Annual Biotech in Europe Forum For Global Partnering & Investment

Selvita reports strong financial results for H1 2020 and a record backlog

Selvita raised over EUR 20 million in its Follow-On public offer

The share issue price in Selvita public offering set at PLN 38

Selvita Extraordinary General Shareholder Meeting decides to proceed with the Follow-On share issue. Initiation of the book-building process on Wednesday, May 27.

Selvita reports financial results for Q1 2020: dynamic increase in backlog for 2020 and strong position on the market

Selvita announces its new development strategy for 2020 – 2023

Selvita and Ardigen will receive funding for the development of an AI-based high-content screening platform

Selvita's Capabilities In Antiviral Drug Discovery

Selvita 2019 financial results: accelerated growth, 43 percent increase in commercial revenues and a very solid backlog for 2020

Update on Selvita current situation and how COVID-19 influences our daily activities

Selvita at BIO-Europe Spring 2020

Selvita as an Innovation Partner of the Inaugural European Targeted Protein Degradation Summit

Selvita to Exhibit at the North American Protein Degradation Congress in San Diego

Selvita Open Days

Selvita to Exhibit at the 37th Medicinal Chemistry Symposium in Tokyo

Selvita Q3 2019 results: accelerated growth, 45 percent increase in commercial revenues and strong long-term outlook

Selvita to Exhibit at the 9th Drug Discovery Innovation Programme

Selvita and Ryvu Therapeutics Announce Independent Trading
on the Warsaw Stock Exchange

Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

Selvita and Sandoz chemists’ research published in Heterocycles

Selvita announces shareholder approval of corporate split and new name of Ryvu Therapeutics for oncology development company

Polish Financial Supervision Authority approves Selvita Cro prospectus, allowing corporate split into two separately listed companies to proceed

Selvita to exhibit at the 20th annual Drug Discovery Summit 2019 Conference

Selvita appoints Tom Coulter as Integrated Drug Discovery Director

Selvita to exhibit at the 14th annual Drug Discovery Chemistry Conference

Selvita to separate oncology therapeutics and contract research business units into two global companies

Selvita introduces new technologies and expands the range of services through PLN 14M infrastructure investments in 2018

Selvita to exhibit at the Elrig Research & Innovation 2019 Conference

Selvita to exhibit at the 3rd annual Drug Discovery Chemistry Conference

Selvita analytical laboratory GMP certifications will be automatically recognized by the FDA

Selvita presents and exhibits at the upcoming Medicinal Chemistry Summit: USA

Selvita and Sandoz chemists published in Bioorganic & Medicinal Chemistry

Selvita promotes Edyta Jaworska to The Management Board to strengthen development in Integrated Drug Discovery services

Selvita exhibits at the 35th Medicinal Chemistry Symposium in Japan

Selvita presents at the 4th Drug Discovery USA Congress

Selvita exhibits at Chemoutsourcing

Selvita will exhibit at 19th RSC/SCI Medicinal Chemistry Symposium

Selvita presents at 18th Drug Discovery Summit in Berlin

Selvita opens new research site in Poznan

Selvita and Sandoz researchers publish paper on Tapentadol synthesis

Selvita will be exhibiting at the 5th MassBio CRO/CMO symposium

Selvita exhibits at 34th Medicinal Chemistry symposium in Japan

Selvita presents at Drug Discovery Congress USA

Selvita announces a ten-year laboratory infrastructure development plan

Selvita exhibits at ChemOutsourcing 2016

Selvita signs a significant collaboration with the University of California, San Francisco (UCSF)

Selvita bridges Krakow and San Francisco

Selvita opens new research site in Poznan

Selvita joins the European network of laboratories EU Netval

Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

Selvita establishes its first operations in the U.S.

Selvita establishes its UK subsidiary in Cambridge

Selvita expands its proteomics services offer

Selvita presents at the 3rd annual Biosimilars & Biobetters congress

Selvita exhibits at the CPHI Worldwide 2014